Show simple record

dc.contributor.authorWhalley, Gillian
dc.contributor.authorSomaratne, Jithendra B.
dc.contributor.authorPoppe, K.K.
dc.contributor.authorter Bals, M.M.
dc.contributor.authorWadams, Gina
dc.contributor.authorPearl, Ann
dc.contributor.authorBagg, Warwick
dc.contributor.authorDoughty, Robert N.
dc.date.accessioned2013-05-21T04:43:35Z
dc.date.available2013-05-21T04:43:35Z
dc.date.issued2011
dc.identifier.urihttps://hdl.handle.net/10652/2132
dc.description.abstractBackground: Left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular disease and is common among patients with type 2 diabetes. However, no systematic screening for LVH is currently recommended for patients with type 2 diabetes. The purpose of this study was to determine whether NT-proBNP was superior to 12-lead electrocardiography (ECG) for detection of LVH in patients with type 2 diabetes. Methods: Prospective cross-sectional study comparing diagnostic accuracy of ECG and NT-proBNP for the detection of LVH among patients with type 2 diabetes. Inclusion criteria included having been diagnosed for > 5 years and/or on treatment for type 2 diabetes; patients with Stage 3/4 chronic kidney disease and known cardiovascular disease were excluded. ECG LVH was defined as either the Sokolow-Lyon or Cornell voltage criteria. NT-proBNP level was measured using the Roche Diagnostics Elecsys assay. Left ventricular mass was assessed from echocardiography. Receiver operating characteristic curve analysis was carried out and area under the curve (AUC) was calculated. Results: 294 patients with type 2 diabetes were recruited, mean age 58 (SD 11) years, BP 134/81 ± 18/11 mmHg, HbA1c 7.3 ± 1.5%. LVH was present in 164 patients (56%). In a logistic regression model age, gender, BMI and a history of hypertension were important determinants of LVH (p < 0.05). Only 5 patients with LVH were detected by either ECG voltage criteria. The AUC for NT-proBNP in detecting LVH was 0.68. Conclusions: LVH was highly prevalent in asymptomatic patients with type 2 diabetes. ECG was an inadequate test to identify LVH and while NT-proBNP was superior to ECG it remained unsuitable for detecting LVH. Thus, there remains a need for a screening tool to detect LVH in primary care patients with type 2 diabetes to enhance risk stratification and management.en_NZ
dc.language.isoenen_NZ
dc.rights© 2011 Somaratne et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly citeden_NZ
dc.subjectLeft ventricular hypertrophy NT-proBNP 12-lead electrocardiography type 2 diabetes cardiovascular diseaseen_NZ
dc.titleScreening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the communityen_NZ
dc.typeJournal Articleen_NZ
dc.rights.holder© 2011 Somaratne et alen_NZ
dc.subject.marsden110201 Cardiology (incl. Cardiovascular Diseases)en_NZ
dc.identifier.bibliographicCitationSomaratne, J. B., Whalley, G. A., Poppe, K. K., ter Bals, M. M., Wadams, G., Pearl, A., ... & Doughty, R. N. (2011). Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community. Cardiovascular diabetology, 10(1), 29.en_NZ
unitec.institutionUnitec Institute of Technologyen_NZ
unitec.peerreviewedyesen_NZ
dc.contributor.affiliationUniversity of Aucklanden_NZ
dc.contributor.affiliationUnitec Institute of Technologyen_NZ
unitec.identifier.roms52075
unitec.institution.studyareaHealth Sciences


Files in this item

Thumbnail

This item appears in

Show simple record